



July 15, 2021 - December 1, 2021
Ketamine: Uses and Abuses
On-demand Encore Virtual Session

ACTIVITY OVERVIEW

On-demand Encore Virtual Sessions consist of recorded CE accredited sessions from the live meeting.

Initially, Ketamine was primarily used for pediatric procedural sedation. Therapeutic uses have expanded to adult and pediatric patients, pain, rapid sequence intubation, refractory depression, refractory neuropathic pain, and more. Learn how ketamine's mechanism of action provides benefit to patients in such different disease states. It is also important to be aware of the potential for ketamine abuse, how to monitor for such abuse, and why ketamine may be abused. Therapeutic uses of ketamine, including the different doses for different therapies will be discussed, as well as monitoring for potential adverse effects, and the potential ways to abuse ketamine.

TARGET AUDIENCE

This educational initiative is intended for Nurse Practitioners, Nurses, Primary Care Physicians and Physician assistants.

LEARNING OBJECTIVES

- Explain how the mechanism of action of ketamine allows it to be used in different clinical situations.
- Create protocols for use, and monitoring such use, of ketamine in emergency departments vs intensive care units vs out-patient clinics.
- Analyze patient symptoms and patterns indicating potential ketamine abuse.

CRITERIA FOR SUCCESS

To obtain a certificate of completion, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at kwolynski@akhcme.com

Please claim credit by December 31, 2021.



Credit provided by AKH, Inc., Advancing Knowledge in Healthcare



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and National Nurse Practitioner Symposium. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Credit being awarded 1.5 ANCC contact hours



AAPA Credit Designation Statement

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/31/2021. PAs should only claim credit commensurate with the extent of their participation.



This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in

Healthcare and National Nurse Practitioner Symposium. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.5 contact hour(s) (which includes 1.5 hour(s) of pharmacology).

Commercial Support

This activity is supported by an educational funding from AstraZeneca Pharmaceuticals and Amgen.

Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

| FACULTY / PLANNERS / REVIEWER DISCLOSURES | | |
|---|--------------|---------------------|
| NAME | RELATIONSHIP | COMPANY |
| Nancy Balch PharmD, BCCCP | N/A | Nothing to disclose |
| Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations | N/A | Nothing to disclose |
| Bernadette Marie Makar, MSN, NP-C, APRN-C- BC- Nurse Planner | N/A | Nothing to disclose |
| NNPS Planners and Reviewers | N/A | Nothing to disclose |
| AKH Planners and Reviewers | N/A | Nothing to disclose |
| All of the relevant financial relationships listed for these individuals have been mitigated. | | |

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.